Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity director Benjamin Regina M. reported transactions on 09/12/2025. The Form 4 shows conversion and movements among Class A and Class B common stock and option activity. The reporting person acquired 5,000 shares of Class A common stock via conversion and exercised a stock option providing the right to buy 5,000 shares at $2.21. Concurrently, 5,000 shares of Class A common stock were sold under a Rule 10b5-1 trading plan at a price of $70.50 per share. After these transactions the reporting person beneficially owned 19,839 shares of Class A and 356,138 shares of Class B common stock (Class B converts 1:1 to Class A).
Doximity director Benjamin Regina M. reported transactions on 09/12/2025. The Form 4 shows conversion and movements among Class A and Class B common stock and option activity. The reporting person acquired 5,000 shares of Class A common stock via conversion and exercised a stock option providing the right to buy 5,000 shares at $2.21. Concurrently, 5,000 shares of Class A common stock were sold under a Rule 10b5-1 trading plan at a price of $70.50 per share. After these transactions the reporting person beneficially owned 19,839 shares of Class A and 356,138 shares of Class B common stock (Class B converts 1:1 to Class A).
Form 144 filed for DOCS: Proposed sale of 5,000 common shares on 09/12/2025 through Morgan Stanley Smith Barney LLC with an aggregate market value of $352,500. The filing states these 5,000 shares were acquired and paid for on 09/12/2025 via a stock option exercise and paid in cash. The filing reports the issuer's total shares outstanding as 187,299,459.
The notice also lists three prior sales by Regina M Benjamin in the past three months: 5,000 shares on 08/08/2025 for $315,000, 5,000 shares on 07/11/2025 for $300,200, and 10,000 shares on 06/25/2025 for $600,000. The filing does not provide the issuer name or filer CIK in the visible fields.
Timothy S. Cabral, a director of Doximity, Inc. (DOCS), reported the automatic sale of 6,360 shares of Class A common stock on 09/02/2025 at a weighted-average price of $66.2981 per share pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. After the reported transactions, Mr. Cabral beneficially owned 3,221 shares of Class A common stock. The filing was signed by an attorney-in-fact on 09/04/2025 and the filer notes the sale prices ranged from $65.83 to $66.64 per share.
The Form 4 discloses that the sales occurred automatically under the established trading plan and the reporting person will provide transaction-level price details upon request.
Insider transactions by Doximity director Kira Scherer on 09/02/2025: The filing shows a conversion and concurrent sale resulting in a net decrease of 1,000 shares of Class A common stock beneficially owned by the reporting person. Specifically, 2,000 shares of Class B were converted into Class A and 2,000 Class A shares were sold at $66.57 each, leaving 19,839 shares of Class A beneficially owned after the sale. The report also discloses derivative holdings: the reporting person holds stock options with a $1.54 exercise price (2,000 option rights) granted June 10, 2020, that vested monthly starting March 27, 2020, and substantial Class B common stock holdings (468,700 shares) that are convertible into Class A under the company charter.
Doximity, Inc. (DOCS) director Phoebe L. Yang received a grant of 3,221 restricted stock units (RSUs) on 08/28/2025 under the company’s non-employee director compensation policy. Each RSU converts to one share of Class A common stock upon vesting. The RSUs vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, subject to the reporting person’s continued service as a director. After the grant, Ms. Yang beneficially owns 17,950 shares of Class A common stock. The grant was reported via Form 4 and executed on 08/28/2025.
Kira Scherer Wampler, a director of Doximity, Inc. (DOCS), was granted 3,221 restricted stock units (RSUs) on 08/28/2025 under the company's non-employee director compensation policy. Each RSU represents a contingent right to one share of the issuer's Class A Common Stock and the award vests in full on the earlier of the first anniversary of the grant date or the issuer's next annual meeting of stockholders, subject to continued service as a director.
Following the reported grant, the reporting person beneficially owns 19,839 shares of Class A Common Stock. The Form 4 was submitted with a signature by an attorney-in-fact on 09/02/2025.
Timothy S. Cabral, identified as a director of Doximity, Inc. (DOCS), was granted 3,221 restricted stock units (RSUs) on 08/28/2025 under the company’s non-employee director compensation policy. Each RSU is a contingent right to one share of Class A Common Stock and was granted at no cash price ($0). The RSUs vest in full on the earlier of the first anniversary of the grant date or the issuer’s next annual meeting of stockholders, subject to continued service as a director. After the grant, the reporting person beneficially owned 9,581 shares of Class A Common Stock.
Benjamin Regina M., a director of Doximity, Inc. (DOCS), received a grant of 3,221 restricted stock units (RSUs) on 08/28/2025 under the issuer's non-employee director compensation policy. Each RSU represents a contingent right to one share of Class A common stock and the grant was reported with a transaction price of $0. The RSUs vest in full on the earlier of the first anniversary of the grant date or the issuer's next annual meeting of stockholders, subject to the reporting person's continued service as a director through the applicable vesting date. After the grant, the reporting person beneficially owned 19,839 shares of Class A common stock on a direct basis. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/02/2025.
Kevin Spain, a director of Doximity, Inc. (DOCS), received 3,221 restricted stock units (RSUs) on 08/28/2025 as compensation under the company’s non-employee director policy. Each RSU converts to one share of Class A common stock and vests in full on the earlier of the first anniversary of the grant or the next annual meeting, subject to continued service. After the grant Mr. Spain directly beneficially owned 9,581 Class A shares, which includes 3,221 RSUs and 6,360 previously vested shares. He also has indirect holdings of 244,607 shares in The Kevin Spain Family Trust and 387,500 shares held by Emergence Capital Opportunity I, L.P., of which he is affiliated; he disclaims beneficial ownership of those indirect holdings except for any pecuniary interest.
Doximity, Inc. (DOCS) filing a Form 144 reports a proposed sale of 6,360 restricted common shares with an aggregate market value of $421,655.28, scheduled approximately for 09/02/2025 on the NYSE. The filing shows the shares were acquired as restricted stock on 08/28/2025 and lists total outstanding common shares of 187,299,459. The filer also disclosed sales during the past three months by Timothy Cabral: 20,000 shares sold on 08/15/2025 for $1,275,566.00 and 10,000 shares sold on 06/25/2025 for $600,000.00. Other customary Form 144 statements and signature cautions are included.